Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Patient Adherence, HIV Seronegativity
Interventions: brief Motivational Interviewing; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • Torrance, California

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 26
States / cities: Anaheim, California • Fountain Valley, California • Los Angeles, California + 21 more

Conditions: Intracerebral Hemorrhage
Interventions: Albumin, Placebo, Brain MRI with and without contrast; Drug · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Surgery, Surgery--Complications, Perioperative/Postoperative Complications
Interventions: Anesthesia Control Tower monitoring; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 79,560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Stargardt's Macular Dystrophy
Interventions: avacincaptad pegol, Sham; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more

Conditions: Diabetes Mellitus
Interventions: Phase 1- Introduction to Dexcom G6 CGM; Device
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Henderson, Nevada

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 26
States / cities: Scottsdale, Arizona • Los Angeles, California • Orange, California + 23 more

Conditions: Healthy
Interventions: JTK-853 or Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hand Eczema
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 23
States / cities: Phoenix, Arizona • Fountain Valley, California • Huntington Beach, California + 18 more

Conditions: Keratolysis
Interventions: Riboflavin, Dextran, UVA Light Source; Drug · Device
Lead sponsor: Joseph B. Ciolino, MD; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 13
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 10 more

Conditions: Bacterial Vaginosis
Interventions: Product 55394, Placebo Vehicle (non-treatment); Drug
Lead sponsor: Medicis Global Service Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Mesa, California + 34 more

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine; Biological
Lead sponsor: Medicago; Industry
Eligibility: 65 Years and older
Enrollment: 12,794 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 50
States / cities: Mobile, Alabama • Tempe, Arizona • Banning, California + 42 more

Conditions: End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
Interventions: Induction therapy, Corticosteroids, EVR+rCNI, MPA+sCNI; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,037 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 40
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 32 more

Conditions: Primary Fibromyalgia
Interventions: TNX-102 SL 2.8mg, Placebo; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: Sacramento, California • Denver, Colorado • Brooksville, Florida + 14 more

Conditions: Influenza
Interventions: favipiravir, placebo; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 147
States / cities: Birmingham, Alabama • Huntsville, Alabama • Camp Verde, Arizona + 123 more

Conditions: Atrial Fibrillation
Interventions: Drug (Direct thrombin or Factor Xa inhibitor); Other
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 10
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 6 more

Conditions: Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Interventions: ASP0113, Placebo; Biological · Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 33
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 26 more

Conditions: Pain, Postoperative
Interventions: Intranasal morphine, Placebo, IV morphine; Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 7
States / cities: Phoenix, Arizona • Bakersfield, California • State College, Pennsylvania + 3 more

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 5,407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Carvedilol, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bipolar Depression
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 56
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more

Conditions: Norovirus Infection
Interventions: VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Fragile X Syndrome
Interventions: Placebo, RO4917523 0.5 mg, RO4917523 1.5 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 14 Years to 50 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Phoenix, Arizona • Long Beach, California • Sacramento, California + 17 more

Conditions: Healthy Volunteers
Interventions: BMS-985521, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Anaheim, California

Search by objective public record fields.

Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Albumin for Intracerebral Hemorrhage Intervention

Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Assessing Non-adjunctive CGM Safety at Home and in New Markets

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

Safety and Efficacy Study to Treat Bacterial Vaginosis

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults

Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation

A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor

Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

Beta-blockers in Pulmonary Arterial Hypertension

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

A Study of RO4917523 in Patients With Fragile X Syndrome

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.